

Outthink. Outperform.

## Break-even now, but when will it be profitable?

Despite turning profitable in 2QFY20, we believe overall results for 6MFY20 still disappointed, as 6MFY20 core loss of RM0.1m was significantly below consensus and our estimates. Consensus and Affin were forecasting PATAMI of RM2.3m and RM3.3m, respectively for FY20E. Although pricing in the tender market has started to improve, it is still not enough to compensate for higher labour costs. As such, we are cutting our EPS forecast for FY20-22E by 7.1-50.6% but maintain our DCF-based TP of RM0.25 unchanged. Reiterate SELL. Karex declared a 0.5 sen interim DPS, which was a positive surprise to us.

### Potential beneficiary of Covid-19

Competition in the tender market has been challenging over the past 2-3 years, due to competition from China manufacturers as they started participating in international contracts after the local government stopped procuring condoms. Management believes that competition has started to ease, as GP margin for tender orders improved (but still below historical average) in recent months. The recent supply disruption in China due to Covid-19 has also resulted in default of several tender orders by the China manufacturers. We believe the current situation could help to expedite the consolidation among the players, which can help to stabilise selling prices.

### Guiding for a better GP margin

Management is guiding future GP margin to be at 25-26%, which is an improvement from the current 21.6% in 2QFY20. We believe the target is achievable only in FY21E, despite the recovery in tender selling price, as Karex is still burdened by the social compliance costs of around RM0.5m/quarter, which will only end in 3QFY20. Once the compensation is fully paid out, we expect a meaningful margin recovery in the following quarters. Karex has also launched its OBM (ONE) into new markets (Thailand, Vietnam and Singapore) recently, which is contributing positively to its margin.

### Maintain SELL with an unchanged TP of RM0.25

Although we expect an improving operating outlook, we are cutting our EPS forecast for FY20-22E by 7.1% to 50.6% to factor in our new margin assumptions. However, we keep our DCF-based TP unchanged at RM0.25 and reiterate our SELL call. Upside risks: better-than-expected recovery in tender orders; cost-effective distribution and marketing.

### Earnings & Valuation Summary

FYE 30 June	2018	2019	2020E	2021E	2022E
Revenue (RMm)	408.0	379.9	411.2	441.2	479.4
EBITDA (RMm)	28.1	20.0	16.4	28.6	48.7
Pretax profit (RMm)	14.3	3.8	2.3	13.5	32.0
Net profit (RMm)	10.1	2.5	1.6	10.6	25.4
EPS (sen)	1.0	0.3	0.2	1.1	2.5
PER (x)	44.6	178.1	280.6	42.5	17.8
Core net profit (RMm)	10.1	2.5	1.6	10.6	25.4
Core EPS (sen)	1.0	0.3	0.2	1.1	2.5
Core EPS growth (%)	(63.8)	(74.9)	(36.5)	560.4	139.1
Core PER (x)	44.6	178.1	280.6	42.5	17.8
Net DPS (sen)	1.0	-	0.5	0.5	0.5
Dividend Yield (%)	2.2	-	1.1	1.1	1.1
EV/EBITDA (x)	15.3	21.0	24.5	15.1	9.2
Chg in EPS (%)			-50.6	-14.3	-7.1
Affin/Consensus (x)			0.7	1.1	3.3

Source: Company, Bloomberg, Affin Hwang forecasts

## Results Note

# Karex

Karex MK  
Sector: Rubber Products

**RM0.455 @ 25 February 2020**

**SELL (maintain)**

Downside: 45%

**Price Target: RM0.25**

Previous Target: RM0.25



## Price Performance

	1M	3M	12M
Absolute	-9.0%	2.2%	5.8%
Rel to KLCI	-4.6%	8.4%	21.6%

## Stock Data

Issued shares (m)	1,002.4
Mkt cap	456.1/107.7
Avg daily vol - 6mth (m)	2.7
52-wk range (RM)	0.39-0.67
Est free float	22.1%
BV per share (RM)	0.49
P/BV (x)	0.93
Net cash/ (debt) (RMm)	9.19
ROE (2020E)	0.3%
Derivatives	No
Shariah Compliant	No

## Key Shareholders

KAREX ONE LTD	18.4%
GOH YIN	7.4%
GOH YEN YEN	7.2%

Source: Affin Hwang, Bloomberg

Ng Chi Hoong  
(603) 2146 7470  
chihoong.ng@affinhwang.com

Outthink. Outperform.

Fig 1: Results Comparison

FYE June (RMm)	2Q FY19	1Q FY20	2Q FY20	QoQ % chg	YoY % chg	6M FY19	6M FY20	YoY % chg	Comments
Revenue	113.6	95.7	109.1	14.0	(3.9)	205.7	204.8	(0.4)	
Op costs	(107.6)	(90.1)	(103.0)	14.4	(4.3)	(193.6)	(193.1)	(0.3)	
<b>EBITDA</b>	<b>5.9</b>	<b>5.7</b>	<b>6.1</b>	7.7	3.2	<b>12.1</b>	<b>11.8</b>	(3.0)	Decline in profit due to higher costs from social compliance cost
<i>EBITDA margin (%)</i>	<i>5.2</i>	<i>5.9</i>	<i>5.6</i>	<i>-0.3ppts</i>	<i>+0.4ppts</i>	<i>5.9</i>	<i>5.7</i>	<i>-0.2ppts</i>	Overall margin still holding up due to increase in contribution from the OBM segment
Depn and amort	(3.9)	(5.3)	(4.5)	(15.5)	13.6	(7.7)	(9.7)	25.6	Increase in 1H20 was due to higher investment in automation
<b>EBIT</b>	<b>2.0</b>	<b>0.4</b>	1.6	314.9	(17.2)	<b>4.4</b>	<b>2.0</b>	(53.4)	
<i>EBIT margin (%)</i>	<i>1.8</i>	<i>0.4</i>	<i>1.5</i>	<i>+1.1 ppts</i>	<i>-0.2 ppts</i>	<i>2.1</i>	<i>1.0</i>	<i>-1.1 ppts</i>	Flow through from EBITDA
Int expense	(0.4)	(0.4)	(0.7)	106.5	89.4	(0.7)	(1.1)	58.9	
Int and other income	0.3	0.2	0.2	(19.4)	(34.5)	0.6	0.4	(29.0)	Due to declining net cash balances
EI	-	-	-			-	-		
<b>Pretax profit</b>	<b>1.9</b>	<b>0.3</b>	<b>1.1</b>	318.8	(41.6)	<b>4.3</b>	<b>1.4</b>	(68.2)	
Tax	(0.4)	(0.1)	(0.2)	89.6	(49.4)	(1.0)	(0.3)	(69.7)	
<i>Tax rate (%)</i>	<i>21.2</i>	<i>40.6</i>	<i>18.4</i>	<i>-22.2 ppts</i>	<i>-2.8 ppts</i>	<i>23.8</i>	<i>22.7</i>	<i>-1.1 ppts</i>	
MI	(0.1)	(0.3)	(0.8)	145.3	926.0	0.1	(1.1)	n.m	
<b>Net profit</b>	<b>1.4</b>	<b>(0.2)</b>	<b>0.1</b>	n.m	(92.7)	<b>3.4</b>	<b>(0.1)</b>	n.m	
EPS (sen)	0.1	(0.0)	0.0	n.m	(92.7)	0.3	(0.0)	n.m	
<b>Core net profit</b>	<b>1.4</b>	<b>(0.2)</b>	<b>0.1</b>	n.m	(92.7)	<b>3.4</b>	<b>(0.1)</b>	n.m	Results missed our and consensus expectations

Source: Affin Hwang, Company

## Important Disclosures and Disclaimer

### Equity Rating Structure and Definitions

<b>BUY</b>	Total return is expected to exceed +10% over a 12-month period
<b>HOLD</b>	Total return is expected to be between -5% and +10% over a 12-month period
<b>SELL</b>	Total return is expected to be below -5% over a 12-month period
<b>NOT RATED</b>	Affin Hwang Investment Bank Berhad does not provide research coverage or rating for this company. Report is intended as information only and not as a recommendation

*The total expected return is defined as the percentage upside/downside to our target price plus the net dividend yield over the next 12 months.*

<b>OVERWEIGHT</b>	Industry, as defined by the analyst's coverage universe, is expected to outperform the KLCI benchmark over the next 12 months
<b>NEUTRAL</b>	Industry, as defined by the analyst's coverage universe, is expected to perform inline with the KLCI benchmark over the next 12 months
<b>UNDERWEIGHT</b>	Industry, as defined by the analyst's coverage universe is expected to under-perform the KLCI benchmark over the next 12 months

This report is intended for information purposes only and has been prepared by Affin Hwang Investment Bank Berhad (14389-U) ("the Company") based on sources believed to be reliable and is not to be taken in substitution for the exercise of your judgment. You should obtain independent financial, legal, tax or such other professional advice, when making your independent appraisal, assessment, review and evaluation of the company/entity covered in this report, and the extent of the risk involved in doing so, before investing or participating in any of the securities or investment strategies or transactions discussed in this report. However, such sources have not been independently verified by the Company, and as such the Company does not give any guarantee, representation or warranty (expressed or implied) as to the adequacy, accuracy, reliability or completeness of the information and/or opinion provided or rendered in this report. Facts, information, estimates, views and/or opinion presented in this report have not been reviewed by, may not reflect information known to, and may present a differing view expressed by other business units within the Company, including investment banking personnel and the same are subject to change without notice. Reports issued by the Company, are prepared in accordance with the Company's policies for managing conflicts of interest. Under no circumstances shall the Company, be liable in any manner whatsoever for any consequences (including but are not limited to any direct, indirect or consequential losses, loss of profit and damages) arising from the use of or reliance on the information and/or opinion provided or rendered in this report. Under no circumstances shall this report be construed as an offer to sell or a solicitation of an offer to buy any securities. The Company its directors, its employees and their respective associates may have positions or financial interest in the securities mentioned therein. The Company, its directors, its employees and their respective associates may further act as market maker, may have assumed an underwriting commitment, deal with such securities, may also perform or seek to perform investment banking services, advisory and other services relating to the subject company/entity, and may also make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report. The Company, its directors, its employees and their respective associates, may provide, or have provided in the past 12 months investment banking, corporate finance or other services and may receive, or may have received compensation for the services provided from the subject company/entity covered in this report. No part of the research analyst's compensation or benefit was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Employees of the Company may serve as a board member of the subject company/entity covered in this report.

Third-party data providers make no warranties or representations of any kind relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages of any kind relating to such data.

This report, or any portion thereof may not be reprinted, sold or redistributed without the written consent of the Company.

This report is printed and published by:  
 Affin Hwang Investment Bank Berhad (14389-U)  
 A Participating Organisation of Bursa Malaysia Securities Berhad

22nd Floor, Menara Boustead,  
 69, Jalan Raja Chulan,  
 50200 Kuala Lumpur, Malaysia.

T : + 603 2142 3700  
 F : + 603 2146 7630  
 research@affinhwang.com

www.affinhwang.com